Chicago Capital LLC Acquires 189,824 Shares of Boston Scientific Co. (NYSE:BSX)

Chicago Capital LLC boosted its holdings in Boston Scientific Co. (NYSE:BSX) by 1,390.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 203,476 shares of the medical equipment provider’s stock after buying an additional 189,824 shares during the period. Chicago Capital LLC’s holdings in Boston Scientific were worth $18,174,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. Values First Advisors Inc. bought a new position in Boston Scientific in the 3rd quarter valued at approximately $28,000. Dunhill Financial LLC raised its stake in Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 152 shares during the last quarter. Global Wealth Strategies & Associates raised its stake in Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 250 shares during the last quarter. West Oak Capital LLC purchased a new stake in Boston Scientific during the 4th quarter valued at $29,000. Finally, E Fund Management Hong Kong Co. Ltd. purchased a new stake in Boston Scientific during the 3rd quarter valued at $30,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BSX has been the subject of several analyst reports. Mizuho upped their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Royal Bank of Canada upped their price objective on Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. BTIG Research upped their price objective on Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Stifel Nicolaus upped their price objective on Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Finally, Wells Fargo & Company upped their price objective on Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $99.73.

Boston Scientific Stock Performance

Boston Scientific stock opened at $102.40 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 1-year low of $62.63 and a 1-year high of $104.25. The firm has a market capitalization of $150.92 billion, a P/E ratio of 84.63, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80. The company’s 50-day moving average is $93.47 and its 200 day moving average is $86.27.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the transaction, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,989 shares of company stock valued at $2,702,261. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.